All In Biotech

Drug Trial Radar · NCT05966194

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 216 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

216

Planned (sponsor's estimate)

Start

Apr 2, 2024

Primary completion

Jul 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
Jul 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.

Conditions

  • Oral Mucositis

Interventions

  • RRx-001Drug

    RRx-001 for injection (4 mg or 8 mg)

  • Intensity Modulated Radiation Therapy (IMRT)Radiation

    Intensity Modulated Radiation Therapy of up to 72 Gy

  • Cisplatin for injection 100 mg/m2Drug

    Cisplatin for injection 100 mg/m2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Severe Oral Mucositis (SOM) through Intensity-modulated radiation therapy (IMRT)Time frame: Estimated up to 18 Months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • Miami Cancer Institute

    Miami, Florida

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • Parkview Cancer Institute

    Fort Wayne, Indiana

  • Willis Knighton Cancer Center

    Shreveport, Louisiana

  • Sandra and Malcolm Berman Cancer Institute

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Renown Regional Medical Center

    Reno, Nevada

  • East Carolina University School of Medicine

    Greenville, North Carolina

  • The Ohio State University James Cancer Hospital & Solove Research Institute

    Columbus, Ohio

  • Ballad Health

    Johnson City, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.